30
CARDIOVASCULAR
hamburger

About the CardioMEMS HF System

The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.

The CardioMEMS HF System is proven to:

  • Aid physicians in preventing worsening heart failure1 and lowering mortality rates2
  • Significantly reduce heart failure hospitalizations3,4
  • Improve quality of life in New York Heart Association (NYHA) Class III patients hospitalized for heart failure in the previous 12 months5

Indications

The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous 12 months. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CARDIOMEMS HF SYSTEM CLINICAL EVIDENCE

Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Highlights from recent real-world data

 
 

62% reduction in heart failure hospitalizations7

62% reduction in heart failure hospitalizations

 

99.6% freedom from device or system related complications6

99.6% freedom from device or system related complications

 

60% reduction in heart failure hospitalization for HFpEF patients6

60% reduction in heart failure hospitalization for HFpEF patients
White CardioMEMS impant profile on gray background

CARDIOMEMS HF SYSTEM EDUCATION AND TRAINING

For safe and reliable HF management with the CardioMEMS HF System, we provide comprehensive educational resources. The following are designed to help you and your patients better understand patient selection, implantation and care.

This device is commercially available for use in select international markets.

References

  1. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
  2. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
  3. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
  4. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.
  5. Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3
  6. Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863
  7. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambula- tory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF) [published online ahead of print, 2020 Jun 27]. Eur J Heart Fail. 2020;10.1002/ejhf.1943. doi:10.1002/ejhf.1943
INDICATIONS, SAFETY & WARNINGS

MAT-2108239 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.